Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.

Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, Kleiner DE, Rotman Y, Ghany MG, Liang TJ, Hoofnagle JH.

Aliment Pharmacol Ther. 2013 May;37(9):887-94. doi: 10.1111/apt.12273. Epub 2013 Mar 6.

2.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf.

PMID:
23395996
3.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

4.
5.

Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.

Mendoza J, Trapero-Marugán M, González-Moreno L, Jones EA, Gómez-Domínguez E, Moreno-Otero R.

Rev Esp Enferm Dig. 2010 Jul;102(7):426-34.

6.

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH.

Dig Dis Sci. 2015 Feb;60(2):573-81. doi: 10.1007/s10620-014-3361-6. Epub 2014 Sep 19.

PMID:
25236421
7.

Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.

Andersen ES, Moessner BK, Christensen PB, Kjær M, Krarup H, Lillevang S, Weis N.

Eur J Gastroenterol Hepatol. 2011 Jan;23(1):41-4. doi: 10.1097/MEG.0b013e328341b891.

PMID:
21079513
8.

Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.

Ogawa E, Furusyo N, Shimizu M, Ihara T, Hayashi T, Harada Y, Toyoda K, Murata M, Hayashi J.

Antivir Ther. 2015;20(2):185-92. doi: 10.3851/IMP2805. Epub 2014 Jun 18.

PMID:
24941012
9.

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.

Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK.

Dig Dis Sci. 2011 Aug;56(8):2449-55. doi: 10.1007/s10620-011-1770-3. Epub 2011 Jun 25.

PMID:
21706207
10.

Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R.

World J Gastroenterol. 2011 Jan 28;17(4):493-8. doi: 10.3748/wjg.v17.i4.493.

11.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
12.

Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.

Ueda Y, Marusawa H, Kaido T, Ogura Y, Oike F, Mori A, Ogawa K, Yoshizawa A, Hatano E, Miyagawa-Hayashino A, Haga H, Egawa H, Takada Y, Uemoto S, Chiba T.

J Viral Hepat. 2012 Jan;19(1):32-8. doi: 10.1111/j.1365-2893.2010.01398.x. Epub 2010 Dec 3.

PMID:
21129128
13.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

14.

High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.

Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB.

Hepatol Int. 2015 Jan;9(1):76-83. doi: 10.1007/s12072-014-9589-6. Epub 2014 Nov 29.

PMID:
25788382
15.

High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.

Chen TM, Lin CC, Huang PT, Wen CF.

Tumour Biol. 2016 Jun;37(6):7129-37. doi: 10.1007/s13277-015-4593-6. Epub 2015 Dec 12.

PMID:
26662957
16.

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

Giannini EG, Basso M, Savarino V, Picciotto A.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):502-8. doi: 10.1111/j.1365-2036.2009.04201.x. Epub 2009 Nov 19.

17.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

18.

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.

Choi SB, Lee YJ, Lee JI, Song YJ, Choi BJ, Kim JH, Jung EU, Park SJ, Lee SH, Kim JH, Choi JS, Jee SR, Seol SY.

Korean J Hepatol. 2011 Sep;17(3):183-8. doi: 10.3350/kjhep.2011.17.3.183.

19.

Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.

Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.

Gastroenterology. 2014 Feb;146(2):442-52.e1. doi: 10.1053/j.gastro.2013.10.012. Epub 2013 Oct 12.

PMID:
24126097
20.

Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.

El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM.

World J Gastroenterol. 2014 Apr 28;20(16):4681-91. doi: 10.3748/wjg.v20.i16.4681.

Supplemental Content

Support Center